• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.更正：阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.
2
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.
3
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.阿巴卡韦/拉米夫定+利匹韦林方案治疗初治HIV-1感染患者的有效性和安全性
J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. doi: 10.1093/jac/dkw347. Epub 2016 Sep 2.
4
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.利匹韦林联合阿巴卡韦和拉米夫定用于病毒载量不可测的HIV-1感染患者的长期疗效和安全性
PLoS One. 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018.
5
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.替诺福韦艾拉酚胺/恩曲他滨与阿巴卡韦/拉米夫定用于治疗病毒学抑制的 HIV-1 感染成人：一项随机、双盲、活性对照、非劣效性 3 期试验。
Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20.
6
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.在接受高效抗逆转录病毒治疗（HAART）且病毒学抑制的HIV感染患者中换用阿巴卡韦/拉米夫定（ABC/3TC）加rilpivirine（RPV）的疗效和安全性。
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):815-9. doi: 10.1007/s10096-016-2602-3. Epub 2016 Feb 15.
7
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.阿巴卡韦/拉米夫定/齐多夫定与依非韦伦每日一次简化疗法治疗HIV-1感染的初步研究。
HIV Clin Trials. 2006 Sep-Oct;7(5):229-36. doi: 10.1310/hct0705-229.
8
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.在常规临床实践中，使用未增强的阿扎那韦联合复方拉米夫定/阿巴卡韦作为一种简化的不含利托那韦的治疗策略。
HIV Clin Trials. 2009 May-Jun;10(3):129-34. doi: 10.1310/hct1003-129.
9
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.更正：埃替格韦/考比司他/恩曲他滨/富马酸替诺福韦二吡呋酯与阿巴卡韦/拉米夫定+多替拉韦在初始治疗中的疗效和安全性间接比较
PLoS One. 2016 Jul 8;11(7):e0159286. doi: 10.1371/journal.pone.0159286. eCollection 2016.
10
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.将齐多夫定/阿巴卡韦/拉米夫定治疗的脂肪萎缩患者转换为洛匹那韦/利托那韦加或不加阿巴卡韦/拉米夫定治疗。
J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5.

本文引用的文献

1
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.

更正：阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全策略：SIMRIKI回顾性研究的48周结果

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

作者信息

Troya Jesús, Ryan Pablo, Ribera Esteban, Podzamczer Daniel, Hontañón Victor, Terrón Jose Alberto, Boix Vicente, Moreno Santiago, Barrufet Pilar, Castaño Manuel, Carrero Ana, Galindo María José, Suárez-Lozano Ignacio, Knobel Hernando, Raffo Miguel, Solís Javier, Yllescas María, Esteban Herminia, González-García Juan, Berenguer Juan, Imaz Arkaitz

出版信息

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.

DOI:10.1371/journal.pone.0172184
PMID:28182783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5300180/
Abstract

[This corrects the article DOI: 10.1371/journal.pone.0164455.].

摘要

[本文更正了文章的数字对象标识符：10.1371/journal.pone.0164455。]